Markets:

Overview

News

Currencies

International

Treasuries

BioCardia, Inc. - Common Stock (NQ:BCDA)

0.9550 +0.0433 (+4.75%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioCardia, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 08, 2022

Via Benzinga

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

December 06, 2022

From BioCardia, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022 ↗

November 11, 2022

Upgrades

Via Benzinga

BioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years ↗

October 03, 2022

Via Benzinga

Earnings Preview For BioCardia ↗

November 08, 2022

BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 09, 2022

Via Benzinga

Recap: BioCardia Q2 Earnings ↗

August 10, 2022

BioCardia (NASDAQ:BCDA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump ↗

April 12, 2022

Via Benzinga

BioCardia Earnings Preview ↗

August 09, 2022

BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will...

Via Benzinga

Executives Buy Around $4M Of 5 Penny Stocks ↗

May 16, 2022

US stock futures traded slightly lower this morning on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...

Via Benzinga

Recap: BioCardia Q1 Earnings ↗

May 11, 2022

BioCardia (NASDAQ:BCDA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings BioCardia beat estimated earnings by...

Via Benzinga

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview For BioCardia ↗

May 10, 2022

BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 06, 2022

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.

Via Benzinga

Follow the Insiders and Buy the Dip in These 3 Stocks ↗

May 06, 2022

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 25, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 21, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

April 19, 2022

Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

Benzinga's Daily Brief On Trending Tickers For April 12, 2022: Veru, Kohl's Corporation, BioCardia, And More ↗

April 12, 2022

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 04, 2022

Via Benzinga

Looking Into BioCardia's Return On Capital Employed ↗

March 30, 2022

Benzinga Pro data, BioCardia (NASDAQ:BCDA) reported Q4 sales of $79.00 thousand. Earnings fell to a loss of $3.46 million, resulting in a 27.9% decrease from last quarter.

Via Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For March 29, 2022 ↗

March 29, 2022

Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.

Via Benzinga

Earnings Outlook For BioCardia ↗

March 28, 2022

BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will...

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 22, 2022

Gainers Revelation Biosciences (NASDAQ:REVB

Via Benzinga

Safety Board Recommends BioCardia's Heart Failure Cell Therapy To Continue Unchanged ↗

February 14, 2022

The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 CardiAMP...

Via Benzinga

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate...

Via Talk Markets

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.